Evidence map›Paper›PMID 19903095›Full record

ReviewCytotherapy2009

Important precautions when deriving patient-specific neural elements from pluripotent cells.

Xuejun H Parsons, Yang D Teng, Evan Y Snyder

Abstract readReview
In one paragraph

Review in Cytotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Current stem cell treatments for spinal cord injury.Indian journal of orthopaedics · 2012
    Article
  10. Article
  11. Article
  12. Article
  13. Cellular treatments for spinal cord injury: the time is right for clinical trials.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2011
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Xuejun H ParsonsDepartment of Cell Biology and Neuroscience, University of California at Riverside, Riverside, California 92521, USA. xuejun.parsons@ucr.edu
Yang D Teng
Evan Y Snyder
Harvard University · USSanford Burnham Prebys Medical Discovery Institute · USSanford Consortium for Regenerative Medicine · US

Funding

Epigenetic Controls in hESC Dopaminergic FateK01AG024496 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PARSONS, XUEJUN H · 2005 to 2009
$610k
Mapping hESC neuronal lineage programmingR21HD056530 · NICHD · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI PARSONS, XUEJUN H · 2009 to 2010
$415k
NIA NIH HHS K01 AG024496NIA NIH HHS K01AG024496NICHD NIH HHS R21 HD056530NICHD NIH HHS R21HD056530
6 · The paper itself

Abstract

Multipotent human neural stem cells (hNSC) have traditionally been isolated directly from the central nervous system (CNS). To date, as a therapeutic tool in the treatment of neurologic disorders, the most promising results have been obtained using hNSC isolated directly from the human fetal neuroectoderm. The propagation ability of such tissue-derived hNSC is often limited, however, making it difficult to establish a large-scale culture. Following engraftment, these hNSC often show low efficiency in generating the desired neuronal cells necessary for reconstruction of the damaged host milieu and, as a result, have failed to give satisfactory results in clinical trials so far. Alternatively, human embryonic stem cells (hESC) offer a pluripotent reservoir for in vitro derivation of a rich spectrum of well-characterized neural-lineage committed stem/progenitor/precursor cells that can, theoretically, be picked at precisely their safest and most efficacious state of plasticity to meet a given clinical challenge. However, the need for 'foreign' biologic additives and multilineage differentiation inclination may make direct use of such cell-derived hNSC in patients problematic. The hNSC, when derived from pluripotent cells under protocols presently employed in the field, tend to display not only a low efficiency in neuronal differentiation, but also an inclination for phenotypic heterogeneity and instability and, hence, increased risk of tumorigenesis following engraftment. For hNSC derived in vitro to be used safely in therapeutic paradigms, it requires conversion of human pluripotent cells uniformly to cells that are restricted to the neural lineage in need of repair. Developing strategies for direct induction of human pluripotent cells exclusively into neural-committed progenies at a broad range of developmental stages will allow a large supply of optimal therapeutic hNSC tailor-made for safe and effective treatment of particular neurologic diseases and injuries in patients.

Indexed as

Stem Cell TransplantationCell DifferentiationCell LineageCell Transformation, NeoplasticHumansInduced Pluripotent Stem CellsMultipotent Stem CellsNervous System DiseasesNeural PlateNeuronsPluripotent Stem Cells

Identifiers

PMID19903095
PMCPMC3449142
OpenAlexW2113986594

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.